Multivalent HVT vector vaccine for poultry
Summary
USPTO granted Patent US12589147B2 to Intervet Inc. for a recombinant herpesvirus of turkeys (rHVT) vector vaccine expressing antigens from IBDV, NDV, and AIV. The patent covers 20 claims and can be used to vaccinate poultry against four diseases: MDV, IBDV, NDV, and AIV simultaneously.
What changed
USPTO granted Patent US12589147B2 to Intervet Inc. on March 31, 2026, covering a recombinant herpesvirus of turkeys (rHVT) engineered as a multivalent vector vaccine for poultry. The rHVT contains three expression cassettes: two inserted in the unique small (Us) region expressing IBDV VP2 and NDV F proteins, and one in the unique long (UL) region expressing AIV HA protein. The patent application (17784838) was filed December 18, 2020, with inventors Martijn Alexander Langereis and Iwan Verstegen.
This patent grant establishes intellectual property protection for Intervet Inc. No immediate regulatory compliance actions are required from other industry participants. Organizations developing similar poultry vaccines should review this patent to assess potential freedom-to-operate concerns and consider licensing discussions with Intervet Inc. if their products fall within the claimed scope.
What to do next
- Review Patent US12589147B2 claims to assess freedom-to-operate for any overlapping vaccine development programs
- Consult with IP counsel if developing competing poultry vector vaccines to evaluate licensing needs
- Update patent landscape documentation to include this granted patent
Archived snapshot
Mar 31, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Multivalent HVT vector vaccine
Grant US12589147B2 Kind: B2 Mar 31, 2026
Assignee
Intervet Inc.
Inventors
Martijn Alexander Langereis, Iwan Verstegen
Abstract
The present invention describes a recombinant herpesvirus of turkeys (rHVT) that can be used as a vector vaccine for poultry against infection and disease from multiple poultry pathogens. Specifically the rHVT expresses an infectious bursal disease virus (IBDV) viral protein 2 (VP2) gene and a Newcastle disease virus (NDV) fusion (F) protein gene from a first and a second expression cassette inserted in the unique small (Us) region, and expresses an avian influenza vims (AIV) haemagglutinin (HA) gene from a third expression cassette inserted in the unique long (UL) region of the genome of said rHVT either between the UL40 and UL41 genes, or between the UL44 and UL45 genes. This rHVT can be used to vaccinate poultry against MDV, IBDV, NDV and AIV.
CPC Classifications
C07K 14/195 C07K 2319/80 C12N 15/86 C12N 2740/16022 C12N 2740/16043 C12N 2710/16043 C12N 2710/16343 C12N 2720/10071 C12N 2710/16034 C12Q 1/18 G01N 2333/16 G01N 2333/165 G01N 2500/10 G01N 33/5091 A61K 2039/5256 A61K 2039/552 A61K 2039/70 A61K 39/12 A61K 39/145 A61K 39/17 A61K 39/245 A61K 39/295 A61P 31/12 A61P 31/16
Filing Date
2020-12-18
Application No.
17784838
Claims
20
Named provisions
Related changes
Get daily alerts for USPTO Patent Grants - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.